.jpg)
1 hour ago
3
Article content
New sales model, expanded evidence base, NCCN guideline inclusion, and growing customer adoption reinforce the value of the ExactVu™ micro-ultrasound platform
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
MARKHAM, Ontario — Exact Imaging, a global leader in high-resolution micro-ultrasound systems for prostate cancer, today reported strong business momentum in calendar year 2025, reflecting progress across commercial execution, clinical validation, and market adoption.
Article content
Article content
During the year, the company implemented a new sales model, expanded the clinical evidence supporting micro-ultrasound–guided prostate imaging, achieved inclusion in leading clinical guidelines, and added new customers across key markets. Together, these developments continue to drive adoption of Exact Imaging’s ExactVu™ micro-ultrasound platform and strengthen commercial traction.
Article content
Article content
“2025 marked an important year of execution for Exact Imaging,” said Randy AuCoin, chief executive officer of Exact Imaging. “We reinforced our commercial foundation while advancing the clinical evidence supporting ExactVu. New customer wins and upcoming 2026 guideline recognition underscore the durability of our growth strategy.”
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Beginning in July 2025, Exact Imaging transitioned to a direct sales model in the United States, expanding its installed base of independent physician practices, academic medical centers, U.S. Department of Veterans Affairs and integrated delivery networks, and improving sales visibility entering 2026. Internationally, Exact Imaging continued to accelerate growth across key international markets through new distributor partnerships and an expanding installed base, driving increased adoption and additional system placements worldwide.
Article content
Exact Imaging also strengthened its clinical foundation, surpassing 100 peer-reviewed publications supporting micro-ultrasound for prostate imaging, including screening, active surveillance, targeted biopsy, and treatment applications. This includes a publication in JAMA demonstrating that ExactVu micro-ultrasound is non-inferior to MRI fusion biopsy for the detection of clinically significant prostate cancer.
Article content
Further validating this body of evidence, the National Comprehensive Cancer Network® (NCCN®) included micro-ultrasound in its 2026 Clinical Practice Guidelines for the Early Detection of Prostate Cancer, recognizing non-inferiority to multiparametric MRI (mpMRI) and mpMRI fusion-guided biopsy.
Article content
“The inclusion of micro-ultrasound in NCCN’s internationally recognized guidelines reflects growing clinical confidence and provides urologists with a guideline-supported diagnostic option,” added AuCoin. “We expect this recognition to further support adoption across a wide range of care settings.”
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
MEDIA CONTACT:
Sam Choinski
Pazanga Health Communications
[email protected]
(860) 301-5058
Article content
Article content
English (US)